OptMed

OptMed is a clinical-stage medical device company focused on developing and commercializing novel surgical adhesives for the localized treatment of trauma and internal injuries. The company's proprietary platform is based on biocompatible polymers originally designed for drug delivery, which have undergone testing for biocompatibility and adhesion, including in wet environments. This pre-revenue company received FDA approval for its BondEase product in 2015, but since then, it has been working to further refine the product while scaling up its production.